ZUMA Press Inc celebrates its' 30th Birthday with another visual spectacular publishing product: www.thePicturesOftheWeek.com
Must see photography Every Friday, as ZUMA brings you The Best Images Of The Last Seven Days, The Week in Review.
Read MoreCrofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program
Read More
Accelerating decision-making at every echelon
Read MoreNet Revenue Expected to Grow 34%+ in 2025 to $4.2 Million, up From Previous Guidance of $4.0 Million
Product Expansion and Growth in Subscription-Based Recurring Revenue Continues to Drive Positive Cash Flow
Read More
New Nationwide Survey Reveals Middle Schoolers Most Likely to Seek Extra Learning Resources to Close Foundational Skills Gaps and Build Confidence
Read More